Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
14.4%
1.19
2.11
0.64
13.16%
-63.4%
46.46
Nifty 500 benchmark
15.2%
0.39
0.58
—
—
-37.3%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
36 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
4,775
-51.8%
13.1%
131.7%
34%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
108%
48%
0.68
11.8%
0.93
26.35
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 36 months this scheme and
Nifty 500 share.
SBI HEALTHCARE OPPORTUNITIES FUND
Regular Plan · Growth
Allocation
By asset
Equity
95.52%
Cash & Equivalents
4.43%
Debt
0.05%
By market cap
Large Cap
34.80%
Mid Cap
27.96%
Small Cap
31.48%
Unclassified
2.60%
Concentration
Number of stocks
36
Top 5 stocks
32.95%
Top 10 stocks
51.83%
Top 20 stocks
76.67%
Lines in the filing
38
Largest holding
11.14%
Largest sector
Pharmaceuticals & Biotechnology 63.10%
Effective stocks
24.1
Sectors held
5
Cash
4.43%
Effective stocks is what the concentration works out to: a fund holding
36 names but most of its money in a few
behaves like a fund of 24. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Pharmaceuticals & Biotechnology
63.10%
Healthcare Services
25.64%
Chemicals & Petrochemicals
4.96%
Cash & Equivalents
4.43%
Healthcare Equipment & Supplies
1.82%
Sovereign
0.05%
SBI HEALTHCARE OPPORTUNITIES FUND
Regular Plan · Growth · holdings
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
Sun Pharmaceutical Industries Ltd.
Pharmaceuticals & Biotechnology
3,600,000
654
11.14%
2
Divi's Laboratories Ltd.
Pharmaceuticals & Biotechnology
500,000
465
7.91%
3
TREPS
Unclassified
—
377
6.42%
4
Acutaas Chemicals Ltd.
Pharmaceuticals & Biotechnology
900,000
295
5.03%
5
Apollo Hospitals Enterprise Ltd.
Healthcare Services
320,000
261
4.45%
6
Torrent Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
540,000
259
4.42%
7
Cipla Ltd.
Pharmaceuticals & Biotechnology
1,920,000
258
4.40%
8
Laurus Labs Ltd.
Pharmaceuticals & Biotechnology
1,200,000
238
4.05%
9
Max Healthcare Institute Ltd.
Healthcare Services
2,400,000
223
3.80%
10
Aurobindo Pharma Ltd.
Pharmaceuticals & Biotechnology
1,200,000
201
3.42%
11
Aster DM Quality Care Ltd.
Healthcare Services
2,700,000
188
3.21%
12
Gland Pharma Ltd.
Pharmaceuticals & Biotechnology
600,000
174
2.96%
13
Sudeep Pharma Ltd.
Chemicals & Petrochemicals
1,360,000
164
2.79%
14
Anthem Biosciences Ltd.
Pharmaceuticals & Biotechnology
1,880,000
161
2.75%
15
Sai Life Sciences Ltd.
Pharmaceuticals & Biotechnology
1,000,000
152
2.60%
16
Corona Remedies Ltd.
Pharmaceuticals & Biotechnology
680,000
142
2.43%
17
Biocon Ltd.
Pharmaceuticals & Biotechnology
3,750,000
139
2.37%
18
Fortis Healthcare Ltd.
Healthcare Services
1,800,000
139
2.36%
19
Concord Biotech Ltd.
Pharmaceuticals & Biotechnology
960,000
132
2.25%
20
Aether Industries Ltd.
Chemicals & Petrochemicals
750,000
127
2.17%
21
Jupiter Life Line Hospitals Ltd.
Healthcare Services
5,000,000
127
2.16%
22
Polymedicure Ltd.
Healthcare Equipment & Supplies
640,000
107
1.82%
23
Ajanta Pharma Ltd.
Pharmaceuticals & Biotechnology
289,791
105
1.79%
24
Global Health Ltd.
Healthcare Services
750,000
102
1.74%
25
Mankind Pharma Ltd.
Pharmaceuticals & Biotechnology
400,000
100
1.71%
26
Healthcare Global Enterprises Ltd.
Healthcare Services
1,500,000
100
1.70%
27
Krishna Institute of Medical Sciences Ltd.
Healthcare Services
1,331,126
99
1.69%
28
Cohance Lifesciences Ltd.
Pharmaceuticals & Biotechnology
2,200,000
98
1.66%
29
Innova Captab Ltd.
Pharmaceuticals & Biotechnology
833,250
97
1.65%
30
Dr. Lal Path labs Ltd.
Healthcare Services
480,000
95
1.62%
SBI HEALTHCARE OPPORTUNITIES FUND
Regular Plan · Growth · where the money sits
What the manager did last month
Between the filings of 30 Jun 2026 and 31 Jul 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹324 cr
₹81 cr
3
2
+5.00%
Stock
Shares traded
Shares
Price
Value ₹ cr
New position
Jupiter Life Line Hospitals Ltd.
4,688,843
entered
—
155
Syngene International Ltd.
1,336,533
entered
—
51.6
Healthcare Global Enterprises Ltd.
588,982
entered
—
39.5
Added to
Cipla Ltd.
660,000
+55.0%
+0.5%
97.2
Sun Pharmaceutical Industries Ltd.
450,000
+15.0%
+6.9%
89.6
Torrent Pharmaceuticals Ltd.
140,000
+38.9%
+10.9%
71.7
Divi's Laboratories Ltd.
50,000
+11.1%
+22.5%
40.3
Global Health Ltd.
80,000
+14.3%
+7.0%
11.2
Nephrocare Health Service Pvt. Ltd.
152,899
+19.1%
+0.6%
10.4
Anthem Biosciences Ltd.
40,000
+2.2%
+5.0%
3.2
Trimmed
Mankind Pharma Ltd.
160,000
-28.6%
-3.0%
39.5
Aether Industries Ltd.
200,000
-20.0%
+13.3%
30.8
Abbott India Ltd.
4,000
-16.7%
+9.3%
11.1
Sold out of
Jupiter Life Line Hospitals Ltd.
900,000
exited
—
128
Lonza Group
160,000
exited
—
102
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
Debt: bills, CDs and commercial paper
₹3 cr
₹3 cr
+₹0 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹1,055,064
₹455,064
22.78%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment
Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 28 Oct 2026.
